Zura Bio Limited (ZURA)
Automate Your Wheel Strategy on ZURA
With Tiblio's Option Bot, you can configure your own wheel strategy including ZURA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZURA
- Rev/Share 0.0
- Book/Share 1.2525
- PB 5.7048
- Debt/Equity 0.0
- CurrentRatio 5.582
- ROIC -0.6127
- MktCap 424602201.0
- FreeCF/Share -0.5658
- PFCF -7.9362
- PE -9.877
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4817
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ZURA | Wedbush | -- | Outperform | -- | $15 | Feb. 9, 2026 |
| Initiation | ZURA | H.C. Wainwright | -- | Neutral | -- | $5 | Sept. 5, 2024 |
News
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.
Read More
About Zura Bio Limited (ZURA)
- IPO Date 2023-03-21
- Website https://zurabio.com
- Industry Biotechnology
- CEO Sandeep C. Kulkarni
- Employees 30